日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Yin-Dan-Ping-Gan Capsule Mitigates CCL(4)-Induced Liver Fibrosis via Regulating PPAR γ/GPX4 Signaling and Suppressing Ferroptosis

银胆平肝胶囊通过调节PPARγ/GPX4信号通路和抑制铁死亡来减轻CCL4诱导的肝纤维化。

Jiang, Xue; Yang, Jicheng; Zhang, Yusheng; Zhang, Ying; Ouyang, Zhen; Zhao, Chen; Lin, Limin; Li, Xianyu; Huang, Luqi

Genetic and Experimental Evidence Implicates CCL4 in Severe Sepsis Risk and Phase-Dependent Immune Dynamics

遗传学和实验证据表明 CCL4 与严重脓毒症风险和阶段依赖性免疫动力学有关

Qin, Qindan; Wang, Yi; Zhang, Li; Li, Zhihua; Wang, Jingjie; Yu, Xiangyou

[Corrigendum] Hypoxia and macrophages promote glioblastoma invasion by the CCL4‑CCR5 axis

【更正】缺氧和巨噬细胞通过CCL4-CCR5轴促进胶质母细胞瘤侵袭

Wang, Ying; Liu, Tao; Yang, Ning; Xu, Shuo; Li, Xingang; Wang, Donghai

WISP-3 facilitates CCL4-dependent monocyte migration and M1 polarization in rheumatoid arthritis by inhibiting miR-6894-5p

WISP-3通过抑制miR-6894-5p促进类风湿性关节炎中CCL4依赖的单核细胞迁移和M1极化。

Wang, Guo-Shou; Lee, Kun-Tsan; Lin, Syuan-Ling; Hou, Sheng-Mou; Fong, Yi-Chin; Tang, Chih-Hsin; Lin, Chih-Yang

Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma

TACC2 的缺失会损害趋化因子 CCL3 和 CCL4 的表达,并降低软组织肉瘤对 PD-1 抑制剂治疗的反应。

Jing Yang # ,Xiuxia Lu # ,Qiyan Cai # ,Mengmeng Liu # ,Tianliang Xia ,Dongchun Hong ,Liyuan Le ,Xinke Zhang ,Xing Zhang

Co-encapsulation of norcantharidin prodrugs and lomitapide in nanoparticles to regulate CCL4 expression by inhibiting Wnt/β-catenin pathway for improved anti-tumor immunotherapy

将去甲斑蝥素前药和洛米他派共封装于纳米颗粒中,通过抑制Wnt/β-catenin通路调节CCL4表达,从而增强抗肿瘤免疫治疗效果。

Feng Zhao # ,Liming Gong # ,Ping Wang # ,Dong Chen ,Shijie Cao ,Feifei Yang ,Manqing Tang ,Yuanyuan Meng ,Yuming Wang ,Lin Miao ,Yunfei Li ,Wei Huang

Correction: CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation

更正:CCL4 通过激活氧化应激和内皮炎症,导致与衰老相关的血管生成不足。

Chang, Ting-Ting; Lin, Liang-Yu; Chen, Ching; Chen, Jaw-Wen

Erratum to "CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease"

更正:“利用纳米颗粒靶向脾酪氨酸激酶 (Syk) 抑制剂,通过 CCL4 介导缓解炎症性肠病”

PROM2 exacerbates CCl4-Induced liver fibrosis via NLRP3 inflammasome activation and hepatocyte pyroptosis.

PROM2 通过 NLRP3 炎症小体激活和肝细胞焦亡加剧 CCl4 诱导的肝纤维化。

Guo Jiashi, Lin Yan, Gong Xia, Kuang Ge, Hu Jun, Du Hui, Liu Hao, Zhang Jiao, Zhang Li, Wan Jingyuan, Wang Ting

FPR1-dependent Pro-inflammatory Ccl4(high) monocytes/macrophages drive and predict sepsis-induced acute lung injury.

FPR1 依赖的促炎性 Ccl4(高)单核细胞/巨噬细胞驱动并预测脓毒症引起的急性肺损伤。